<html>
<head>PUBMED IDs for FGFBP2</head>
<body bgcolor='#C5F0F2'><h1>FGFBP2</h1><a href='https://pubmed.ncbi.nlm.nih.gov/19915711/'>Change in mRNA Expression after Atenolol, a Beta-adrenergic Receptor Antagonist and Association with Pharmacological Response.</a> November 17  2009<br><a href='https://pubmed.ncbi.nlm.nih.gov/20190191/'>Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenstrom macroglobulinemia but exhibit anergic properties and are eliminated by nucleoside analogue therapy.</a> May 21  2010<br><a href='https://pubmed.ncbi.nlm.nih.gov/21079801/'>POLD2 and KSP37 (FGFBP2) correlate strongly with histology, stage and outcome in ovarian carcinomas.</a> April 28  2010<br><a href='https://pubmed.ncbi.nlm.nih.gov/22745584/'>The IGR-CaP1 xenograft model recapitulates mixed osteolytic/blastic bone lesions observed in metastatic prostate cancer.</a> November 8  2012<br></body></html>
